CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days
The Indian Hotels Company Ltd. 24/08/2023401.85517.9007/02/2024 28.88% 167 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Is The Pharmaceutical Industry Shaping Up To Be The New IT?
Ninad Ramdasi

Is The Pharmaceutical Industry Shaping Up To Be The New IT?

US Drug Shortages and India’s Competitive Advantage

Given the shared traits between the pharmaceutical and IT industries, it’s worth pondering whether the pharmaceutical industry is on its way to becoming the new IT. Mandar Wagh delves into the dynamics of the US drug shortage, India’s competitive edge and the technological revolution within the industry, all of which are setting the stage for unparalleled growth 

Over the past few months, the Indian benchmark indices have witnessed a significant rally, breaking away from their previously observed range-bound fluctuations. This momentum has propelled the indices to attain unprecedented highs, consequently leading to gains of around 10-11 per cent for both the BSE Sensex and Nifty 50 over the past six months. The robust performance can be attributed to an overarching positive sentiment that goes beyond the broader market and encompasses specific industries as well. Notably, Nifty Pharma, an index tracking the pharmaceutical industry, has demonstrated exceptional resilience. 

Previous Article 3,240 per cent returns: This multibagger small-cap company announces expansion plan to increase distillery capacity to 850 KLPD; aims for Rs 550 crore revenue!
Next Article Penny Stock Due Diligence
Print
668 Rate this article:
4.6
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR